New Metabolizable Immunologic Adjuvant for Human Use

PREVIOUS reports by our group1 2 3 4 5 6 described the development and clinical evaluation of a new immunologic adjuvant, named adjuvant 65, which was applied to influenza-virus vaccine. The adjuvant preparation consisted of a water-in-peanut-oil emulsion of the aqueous vaccine employing mannide mono-oleate (Arlacel A) as emulsifier and aluminum monostearate as stabilizer. A detailed analytic review of all the available data on adjuvants and adjuvant 65 has been reported elsewhere.7 The desirability for maximal purity of antigens included in adjuvant formulations led to the development of a highly purified aqueous influenza-virus vaccine that has been tested both as aqueous material and incorporated into . . .